• June 16-19, 2025
  • Boston Convention & Exhibition Center

Sessions

Loading

Diakonos Oncology

Tuesday, June 04, 2024
Company Presentation
Oncology
Company Presentation Theater 2
Clinical Efficacy in the Toughest Cancers -- Cracking the Code on Dendritic Cell Therapy and Tumor Infiltrating Lymphocytes Diakonos Oncology is developing two cell therapy technologies developed at MD Anderson and Baylor College of Medicine. The seed-stage company is in a unique position due to early clinical progress achieved under an investigator sponsored protocol for the lead asset, DOC1021. The Phase 1 study in “moonshot” GBM patients is now fully enrolled (n=18) with topline data expected in 1H24. To date, interim median PFS is 9+ mo. (vs 4 mo. expected) and interim average survival for Cohort 1 (low dose, n=3) is 19.8+ mo. (vs 15 mo. expected). Clinical benefits have been observed in multiple (10+) other cancer types in IST and IST-like settings (incl. 4/5 CRs in PDAC patients). Fast Track & Orphan Drug Designation have been awarded for DOC1021 based on 1) observed survival benefit in GBM Phase 1 and 2) no attributable Serious Adverse Events (SAEs) to date.
Diakonos Oncology
Company Website: https://www.diakonosoncology.com/
Lead Product in Development: DOC1021
Number Of Unlicensed Products (For Which You Are Seeking Partners): 3

Company HQ City

Houston

Company HQ State

Texas

Company HQ Country

United States

CEO/Top Company Official

Mike Wicks

Development Phase of Primary Product

Phase I
Primary Speaker
Anthony Baldor, MBA
CFO and Head of Business Development
Diakonos Oncology
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS